October 05, 2022
Article
Research findings suggest that SLIT2 loss in circulating tumor cells promotes metastasis and enhances cancer progression, according to a Northwestern Medicine study published in Science Advances.
October 04, 2022
The talazoparib/enzalutamide combination was also shown to have benefits in key secondary end points, including prostate specific antigen (PSA) response, time to PSA progression, and overall response rate.
“Men with this type of metastatic prostate cancer want to get their genetically targeted therapy as early as possible, and this trial clearly shows the value of rucaparib as a treatment for these men,” said Alan H. Bryce, MD, principal investigator of the TRITON3 trial.
September 30, 2022
Cell-free DNA–based next-generation sequencing profiling resulted in low detection/concordance in clear cell renal cell carcinoma.
September 19, 2022
Video
“There’s a tremendous amount of work going on right now with PARP inhibitors in the resistant stage, but now also we’re looking at them in the sensitive stage,” says Neal D. Shore, MD.
September 13, 2022
The presence of more than 2 tertiary lymphoid structures coupled with increased density of Ki-67 and PD-1 positivity was linked to an increased response rate and prolonged progression-free survival.
September 08, 2022
In a phase 2 trial, patients with metastatic urothelial carcinoma and DNA repair deficiency who had not progressed on chemotherapy were randomized to either rucaparib maintenance or placebo.
September 06, 2022
In the study, certain pathologic variants were associated with higher incidence of prostate cancer vs non-carrier controls.
August 23, 2022
The ClarityDX Prostate test assesses a combination of clinical and biological biomarker data and provides a risk score that a patient biopsy would show a clinically significant prostate cancer.
August 22, 2022
Albert Jang, MD, discusses the promise of using ctDNA to determine whether patients with advanced genitourinary cancers are responding to immune checkpoint inhibitors.
